Brought to you by 
Veridex, Mass Gen work on circulating tumor cell technology
23 Apr 2020
Executive Summary
Johnson & Johnson’s Veridex LLC (cancer diagnostics) and Massachusetts General Hospital will together develop and market a next-generation circulating tumor cell (CTC) technology to capture, count, and characterize tumor cells located in a patient’s blood. The five-year deal is worth $30mm, consisting of a technology license fee and milestones, plus royalties.
Deal Industry
- In Vitro Diagnostics
- Pharmaceuticals
-
In Vitro Diagnostics
- Chemistry, Immunoassay
-
Biotechnology
- Drug Discovery Tools
Deal Status
- Final
Deal Type
-
Alliance
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Veridex, Mass Gen work on circulating tumor cell technology
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice